Classification ![]() |
|
| Compound class | Antibody |
| Approved drug? | Yes (source: FDA (2000)) |
| Withdrawn drug? | Yes |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 10315 | gemtuzumab ozogamicin |
Synonyms ![]() |
| CDP 771 |
| CMA 676 |
| hP67.6-calicheamicin |
| Mylotarg® |
| WAY-CMA 676 |
Database Links ![]() |
|
| Specialist databases | |
| IMGT/mAb-DB | 44 |
| Other databases | |
| PubChem SID | 178103381 |
| Search PubMed clinical trials | gemtuzumab ozogamicin |
| Search PubMed titles | gemtuzumab ozogamicin |
| Search PubMed titles/abstracts | gemtuzumab ozogamicin |
| Wikipedia | Gemtuzumab_ozogamicin |
| Comments |
| This drug is an antibody-drug conjugate (ADC) that targets delivery of the highly cytotoxic ozogamicin (a derivative of calicheamicin γ1) to CD33 +ve myeloid cells [1]. |